Chronic Myeloid Leukemia with a Complex Variant ‘Ph’ Translocation That Develops in Breast Carcinoma, Postchemotherapy: A Rare but Treatable Entity.
10.4048/jbc.2017.20.2.208
- Author:
Gargi TIKKU
1
;
Monica JAIN
;
Pragya SHUKLA
Author Information
1. Department of Oncopathology, Delhi State Cancer Institute, Delhi, India. gargi.tikku@gmail.com
- Publication Type:Case Report
- Keywords:
Breast neoplasms;
Chemotherapy;
Chronic-phase myeloid leukemia
- MeSH:
Breast Neoplasms*;
Breast*;
Carcinoma, Ductal;
Chromosomes, Human, Pair 17;
Cyclophosphamide;
Doxorubicin;
Drug Therapy;
Epidermal Growth Factor;
Estrogens;
Female;
Fluorouracil;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Mastectomy, Modified Radical;
Middle Aged;
Prognosis;
Receptors, Progesterone;
Recurrence
- From:Journal of Breast Cancer
2017;20(2):208-211
- CountryRepublic of Korea
- Language:English
-
Abstract:
We report a case of chronic myeloid leukemia (CML) that developed after postoperative chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) for breast cancer. A 55-year-old woman was diagnosed with invasive ductal carcinoma which was treated with a modified radical mastectomy followed by six cycles of CAF chemotherapy. Nine years later, she developed CML and locoregional recurrence. Her breast recurrence showed strong estrogen receptor, weak progesterone receptor and strong human epidermal growth factor 2 (score 3+) expression. Her secondary CML in the chronic phase showed a complex variant translocation (CVT) involving chromosomes 9, 22, and 17. Considering that the HER2/neu gene is also located on chromosome 17, this secondary CML in chronic phase with CVT is indeed a rare occurrence. We discuss the associated genetic factors and the possible role of breast cancer chemo/radiotherapy in the development of such CML as well as its treatment and prognosis compared with de novo CML.
